Cancer CAR-T therapy 'jumps' to frontline in high-risk lymphoma trial
The director of the International Breast Cancer Center (IBCC) and first author of the international clinical trial Destiny Breast-03,
Javier Cortés,
has highlighted that the drug 'trastuzumab deruxtecan'
"improves" progression-free survival of
HER2-positive breast cancer in 75.8% of the patients.
The magazine 'The New England Journal of Medicine' has published the results of this study which, according to Cortés, are
"the most positive in the history" of breast cancer
after analyzing the efficacy and safety of the drug, the IBCC reported in a statement this Wednesday.
In fact, the results with this drug have been "so positive" that trastuzumab deruxtecan has become, according to the IBCC, the
new standard of second-line treatment
for patients with HER2-positive breast cancer.
It is a phase III, randomized, multicenter, international clinical trial, carried out with the participation of 524 patients with HER2-positive metastatic breast cancer, recruited for this trial between July 20, 2018 and June 23, 2020 in 169 centers in 15 countries.
Of the total, 261 patients were randomly assigned to the arm of the study in which they received 'trastuzumab deruxtecan' and 263, to the arm of the treatment, until then the standard, consisting of 'trastuzumab emtansine' (TDM-1).
One of the "most important" results of the study has been the
improvement in progression-free survival
(that is, disease control), which
has been 75.8%
in these patients at 12 months, compared to 34 .1% in the group of patients treated with 'trastuzumab emtansine'.
The preliminary results of Destiny Breast-03 were presented at the presidential session of the Congress of the European Society for Medical Oncology (Esmo) last September and its publication now in 'The New England Journal of Medicine' confirm its "robustness".
"TROY HORSE"
It is an immunoconjugate that acts as a "Trojan horse" because it
circumvents the defenses of tumor cells to enter them
and attack them by releasing their load, it is composed of a monoclonal antibody (trastuzumab), joined by a linker or bonding to molecules chemotherapy (deruxtecan).
It is administered intravenously and travels through the blood to the tumor cells, where it recognizes the gateway of these malignant cells, in this case the HER2 receptor, enters undetected and releases the chemotherapy it carries to destroy them, without damaging "so much" other healthy cells.
Conforms to The Trust Project criteria
Know more
breast cancer
Cancer
HealthAfter 30 years, a new approach to early-stage lung cancer is making its way
SaludIzpisúa: "We are not looking for human beings to live another hundred years, but to slow down the deterioration of aging"
Covid-19The Danish post-Covid "normalization" invites optimism
See links of interest
Last News
Time change 2022
Oscars movies where to watch
Oscar nominees
best colleges
It is written to have or to see
Topics
Work calendar 2022
Bitci Baskonia - Fenerbahce Istanbul